Jeanne Moody
Overview
Explore the profile of Jeanne Moody including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buzard D, Schrader T, Zhu X, Lehmann J, Johnson B, Kasem M, et al.
Bioorg Med Chem Lett
. 2014 Dec;
25(3):659-63.
PMID: 25532755
Modulators of S1P1 have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P1 chemotypes...
2.
Buzard D, Lopez L, Moody J, Kawasaki A, Schrader T, Kasem M, et al.
ACS Med Chem Lett
. 2014 Dec;
5(12):1334-9.
PMID: 25516794
S1P1 is a validated target for treatment of autoimmune disease, and functional antagonists with superior safety and pharmacokinetic properties are being sought as second generation therapeutics. We describe the discovery...
3.
Buzard D, Kim S, Lopez L, Kawasaki A, Zhu X, Moody J, et al.
ACS Med Chem Lett
. 2014 Dec;
5(12):1313-7.
PMID: 25516790
APD334 was discovered as part of our internal effort to identify potent, centrally available, functional antagonists of the S1P1 receptor for use as next generation therapeutics for treating multiple sclerosis...
4.
Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease
Buzard D, Han S, Lopez L, Kawasaki A, Moody J, Thoresen L, et al.
Bioorg Med Chem Lett
. 2012 May;
22(13):4404-9.
PMID: 22633692
Two series of fused tricyclic indoles were identified as potent and selective S1P(1) agonists. In vivo these agonists produced a significant reduction in circulating lymphocytes which translated into robust efficacy...
5.
Buzard D, Han S, Thoresen L, Moody J, Lopez L, Kawasaki A, et al.
Bioorg Med Chem Lett
. 2011 Aug;
21(19):6013-8.
PMID: 21852130
S1P(1) receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P(1) receptor...